(Reuters) - The U.S. Food and Drug Administration on Tuesday rejected Prevention Bio Inc.'s approval of the experimental diabetes drug teplizumab, citing insufficient data,...
Late breaking poster presentation with full 12-month follow-up results and 6-month crossover patient data for SENZA-PDN randomized controlled trialCompany to hold investor briefing on...